Rare Condition Linked to Lamotrigine Requires Quick Action
Summary
Researchers studied two patients who developed a serious condition called haemophagocytic lymphohistiocytosis (HLH) after starting a medication called lamotrigine, which is often used to treat epilepsy. HLH is a rare but dangerous syndrome that causes severe inflammation in the body. The patients experienced symptoms like high fever and low blood cell counts shortly after beginning lamotrigine and required intensive medical care.
The key findings showed that both patients developed HLH within ten days of starting lamotrigine. They exhibited the classic signs of HLH, which include fever, falling blood cell counts, and high levels of a protein called ferritin. After stopping lamotrigine and receiving treatment, both patients recovered and were able to switch to other medications for their seizures without further issues.
This study highlights the importance of being aware of the potential risks associated with lamotrigine, particularly the rare chance of developing HLH. While both patients recovered, it emphasizes the need for careful monitoring and quick action if symptoms arise. However, since this is based on only two cases, more research is needed to understand how often this happens and to improve safety for those taking lamotrigine.
Related reading
- Genetic Risk Linked to Brain Changes in Children with Epilepsy
- Effective Treatments for Pyridoxine-Dependent Epilepsy in Children
- Managing Suicidal Thoughts Linked to Levetiracetam Treatment
- Effective Therapies for Anxiety and Depression in Epilepsy
- Understanding Insular Epilepsy and Its Seizure Signs
- Oral Health Challenges for People with Epilepsy
